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The current European Society for Immunodeficiencies
(ESID) registry was established 10 years ago in 2004, when
the system was moved from a paper-based to an online
system. The purpose of the registry is to collect data on
European patients with primary immunodeficiencies
(PIDs) and their treatment, with the aim of building an
easily accessible database for use by physicians and research-
ers.
During the 10 years for which the current registry has
been operational, the number of patients registered has
grown substantially; after 4 years, more than 7000 patients
were registered and, as of 25 June, 19 355 patients are regis-
tered in Europe as having a PID. Longitudinal data (20 or
more data sets, documented every 6 months) is now avail-
able for some of the patients in the registry. Children
younger than age 15 years represent two-thirds of this
cohort. More than half the patients (57%) have an antibody
disorder, and this is also the group with the greatest number
of adult patients. Of the 19 355 registered, treatment data
are available on approximately 14 000, of whom 6476
receive immunoglobulin (Ig) treatment; 4239 patients are
receiving intravenous immunoglobulin (IVIg) treatment
and approximately 2181 receive subcutaneous immuno-
globulin (SCIg).
One of the interesting comparisons arising from the reg-
istry data is the difference in minimum prevalence of PIDs
between countries. In France, for example, 6·058 cases are
documented per 100 000 inhabitants; much higher than in
Switzerland (4·157 per 100 000) or Germany (2·105 per
100 000). This is most probably because France has a very
efficient documenting system, whereby designated
documenters, financed by local grants in France, visit
centres to enter patients’ data into the registry. Thus, the
more efficient the documenting system, the higher the
quality of data collected.
Physicians and researchers can apply for access to the reg-
istry data by writing to ESID with details of their specific
project, or with a proposal to collect new and different data
on patients with specific diseases. Despite the large number
of patients in the registry and the large amount of data col-
lected, only 23 papers have been published, which is an
average of more than two per year over 10 years. However,
considering that more than 200 physicians and researchers
have access to the database, this still means that the registry
is one of the most under-used data sets of its kind in
Europe.
In a recent registry publication we analysed the subset of
common variable immunodeficiency (CVID) subjects [1].
There are more than 4000 CVID subjects in the registry, but
because not all have complete data sets, the cohort
described in this paper included 2212 subjects.
As CVID has a variable clinical presentation, we investi-
gated the frequencies of different disease phenotypes in the
cohort [1]. The most common clinical features were pneu-
monia (32%) and autoimmunity (29%). Other features
included splenomegaly (26%), bronchiectasis (23%) and
granulomatous disease (10%), and a further 10% had enter-
opathy. Surprisingly, 5% of patients had solid tumours and
4% had meningitis/encephalitis [conditions associated
more usually with X-linked agammaglobulinaemia (XLA)].
Less frequent clinical features were lymphoma, found in 3%
of the patients, splenectomy in 2% and lobectomy in 1%.
With regard to how efficiently patients are being diag-
nosed, CVID has been described as having a bi-modal age
of manifestation, with a peak in diagnoses between the ages
of 5 and 10 years, a trough around the age of 20, and then
another peak between 30 and 40 years. However, when
patients are asked about the onset of their symptoms the
reported age is lower, with most patients experiencing
recurrent infections in childhood, and fewer than half
manifesting after age 20 (Fig. 1). In some countries, the
delay between onset of symptoms and CVID diagnosis is
greater than others, the average being 4·1 years, ranging
from 1·8 years in Poland to 7 years in France [1].
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We showed that adult CVID cases were diagnosed
more promptly than paediatric cases (aged <10 years),
suggesting that educational programmes may be required
to raise awareness of CVID in general practitioners and
paediatricians.
To ascertain whether the diagnostic delay had improved
during the last 20 years, we compared age of onset and time
of diagnosis, grouped into 3-year intervals, between 1987
and 2010. Throughout that period, we found no improve-
ment in the diagnostic delay (P = 0·14).
Our study also highlighted the variation in the dose of Ig
being administered to CVID patients in centres across
Europe. This is accounted for by variations in dosing regi-
mens; for example, one of the highest median monthly
doses was recorded at Barts and the London Hospital,
where the policy is to start patients on very high doses to
raise their Ig trough levels quickly, and then subsequently
reduce the dose. This centre has a median monthly dosage
per patient of 711 mg/kg body weight. In contrast, the
centre in Prague had the lowest median monthly dose per
patient of 129 mg/kg body weight, due partly to problems
with reimbursement of adult patients for Ig treatment.
Since the assessment was carried out, the Czech health
authorities have altered their policies.
As shown by Orange et al. [2], the CVID subregistry
analysis indicated that higher Ig trough levels correlated
with fewer serious infections in this cohort. Nevertheless,
higher Ig trough levels did not affect the number of days
patients spent in hospital. This is due most probably to the
fact that, as CVID has such a variety of symptoms, patients
are not only hospitalized for infections, but for other
comorbid disease including autoimmune conditions, enter-
opathy and lymphoma.
Finally, we compared outcomes for CVID patients receiv-
ing IVIg and those receiving SCIg treatment. We concur
with previously published results [2] showing that higher
trough Ig levels lead to a reduction of serious infections
in patients receiving IVIg, but this could not be shown
in the patients receiving SCIg. One possible reason is that
physicians are administering SCIg to relatively healthy
patients and reserving IVIg for those who are more severely
ill, but only a prospective clinical trial will resolve this
question.
The registry has recently been redesigned to increase the
quality and completeness of data collected in the database.
The new system now has three levels of data collection: level
1 encompasses data fields that are mandatory for all who
are registered, thus enabling epidemiological studies. Levels
2 and 3 are optional, with level 2 including diagnostic and
follow-up data, and level 3 will comprise projects running
for limited time-periods to collect data for use in clinical
studies.
For the last 10 years, the ESID registry has been funded
primarily by the Plasma Protein Therapeutics Association
(PPTA) and pharmaceutical company sponsorship. The
total cost of the ESID registry has been estimated at
approximately €2 million per year, with much of the cost
being shouldered by the documenting centres whose
doctors, nurses and students record data into the registry.
The PPTA has recently withdrawn its funding of the regis-
try, and we envisage the need for core support from the
pharmaceutical industry, to support level 3 projects espe-
cially, and allow the registry to continue to evolve as a useful
tool for research, diagnosis and treatment in the field of
PIDs.
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Fig. 1. (a) Age at onset of symptoms in the
total cohort (n = 1914), among female patients
(n = 985) and among male patients (n = 929).
(b) Age at diagnosis in the total cohort
(n = 2134), among female patients (n = 1094)
and among male patients (n = 1040). An age of
0 years means less than 12 months of age
(reproduced from [1], copyright 2014, with
permission from Elsevier).
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